Bucillamine NEW
| Price | $33 | $56 | $93 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Bucillamine | CAS No.: 65002-17-7 |
| Purity: 99.47% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Bucillamine |
| Description | Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis. |
| In vivo | In rats subjected to liver transplants, Bucillamine significantly enhances survival and protected against hepatic injury[2]. Subconjunctival injection of Bucillamine significantly reduces the leakage and size of experimental CNV in rats[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 252.5 mg/mL (1130.72 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (44.78 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (44.78 mM), Solution. |
| Keywords | VEGFR | Vascular endothelial growth factor receptor | SA-96 | SA 96 | rheumatoid arthritis | Ischemia/reperfusion | Inhibitor | inhibit | choroidal neovascularization | Bucillamine | antirheumatic | antioxidant | antiangiogenic |
| Inhibitors Related | Ribociclib | Maltol | Sorafenib | AFMK | DL-alpha-Tocopherylacetate | Neohesperidin | Sulbutiamine | L-Cystine | γ-Terpinene | Tyrosol | 4-hydroxyphenylacetic acid | Pazopanib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2026-02-02 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-09-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY